Axovant Sciences Stock Price, News & Analysis (NASDAQ:AXON)

$4.99 -0.04 (-0.80 %)
(As of 11/20/2017 02:52 AM ET)
Previous Close$5.03
Today's Range$4.96 - $5.21
52-Week Range$4.60 - $27.98
Volume1.07 million shs
Average Volume1.03 million shs
Market Capitalization$537.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.01

About Axovant Sciences (NASDAQ:AXON)

Axovant Sciences logoAxovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:AXON
  • CUSIP: N/A
  • Web: www.axovant.com
Debt:
  • Debt-to-Equity Ratio: 0.34%
  • Current Ratio: 5.94%
  • Quick Ratio: 5.94%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $1.26 per share
  • Price / Book: 3.96
Profitability:
  • Trailing EPS: ($2.30)
  • Net Income: ($180,950,000.00)
  • Return on Equity: -146.93%
  • Return on Assets: -97.18%
Misc:
  • Employees: 69
  • Outstanding Shares: 107,710,000
 

Frequently Asked Questions for Axovant Sciences (NASDAQ:AXON)

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd. (NASDAQ:AXON) issued its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.12. View Axovant Sciences' Earnings History.

When will Axovant Sciences make its next earnings announcement?

Axovant Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Axovant Sciences.

Where is Axovant Sciences' stock going? Where will Axovant Sciences' stock price be in 2017?

11 Wall Street analysts have issued 12-month target prices for Axovant Sciences' stock. Their forecasts range from $3.00 to $30.00. On average, they expect Axovant Sciences' share price to reach $14.68 in the next twelve months. View Analyst Ratings for Axovant Sciences.

What are Wall Street analysts saying about Axovant Sciences stock?

Here are some recent quotes from research analysts about Axovant Sciences stock:

  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (11/9/2017)
  • 2. HC Wainwright analysts commented, "We hosted a conference call with a medical physicist on October 17, 2017. The consultant highlighted a number of key benefits associated with ViewRay’s MRI-Cobalt and MRI-LINAC as well as main differences between ViewRay’s low-T MRIdian technology and competitor Elekta’s yet-to-be approved High- T Unity system. Replay information available upon request. KeyPoints High-T vs. Low-T. While in the context of a diagnosis, a high-T system would surely lead to greater image resolution, the low-T system appears more suitable in the treatment phase where the key lies in the ability to locate the patient’s tumor in a dynamic way. Image quality, it turns out, can be improved through various techniques according to our consultant." (10/19/2017)
  • 3. Piper Jaffray Companies analysts commented, "We see these results as mixed but positive for the company's first foray into this under-studied disease. First off, nelo' did appear safe/well tolerated, which was a non-zero risk in this population. In addition, the study suggested some benefit on ADL and motor function ' not exactly what we were expecting, but if replicated could address a key unmet need in DLB especially. We didn't yet see improvement on visual hallucinations but longer dosing in more patients may be helpful here. We'll await full results around mid'17, and remain optimistic these results and/or the DLB-RBD study will inform a Phase III program for nelo' in at least one LBD symptom complex. For now, nelo' is upside to our valuation and we remain focused on the pivotal programs for RVT-101 in AD and DLB." (2/13/2017)

Who are some of Axovant Sciences' key competitors?

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the folowing people:

  • Marion McCourt, President, Chief Operating Officer (Age 57)
  • David T. Hung M.D., Chief Executive Officer, Director (Age 60)
  • Gregory M. Weinhoff M.D., Chief Financial Officer (Age 46)
  • Vivek Ramaswamy, Director, Chief Executive Officer - Roivant Sciences (Age 31)
  • Mark Altmeyer, President of Axovant Sciences GmbH and Chief Commercial Officer (Age 56)
  • Eric Floyd Ph.D., Senior Vice President - Regulatory Affairs
  • Ilise Lombardo M.D., Senior Vice President - Clinical Research
  • Thomas Templeman Ph.D., Senior Vice President - Pharmaceutical Operations and Quality Assurance
  • Mark Wadley, Senior Vice President, US Business
  • Samina Bari, Vice President - Corporate Communications

When did Axovant Sciences IPO?

(AXON) raised $251 million in an initial public offering (IPO) on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who owns Axovant Sciences stock?

Axovant Sciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SVF INVESTMENTS (UK) LTD (69.80%), OxFORD Asset Management LLP (0.81%), Eagle Asset Management Inc. (0.56%), Artal Group S.A. (0.46%), Prudential Financial Inc. (0.20%) and Ameriprise Financial Inc. (0.18%). Company insiders that own Axovant Sciences stock include David Hung, Mark Altmeyer and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences.

Who sold Axovant Sciences stock? Who is selling Axovant Sciences stock?

Axovant Sciences' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, C WorldWide Group Holding A S and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Axovant Sciences.

Who bought Axovant Sciences stock? Who is buying Axovant Sciences stock?

Axovant Sciences' stock was bought by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP, Eagle Asset Management Inc., Artal Group S.A., Ameriprise Financial Inc., Prudential Financial Inc., Wells Fargo & Company MN, Cubist Systematic Strategies LLC and Oppenheimer & Co. Inc.. Company insiders that have bought Axovant Sciences stock in the last two years include David Hung, Mark Altmeyer and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences.

How do I buy Axovant Sciences stock?

Shares of Axovant Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of Axovant Sciences stock can currently be purchased for approximately $4.99.

How big of a company is Axovant Sciences?

Axovant Sciences has a market capitalization of $537.47 million. The biotechnology company earns ($180,950,000.00) in net income (profit) each year or ($2.30) on an earnings per share basis. Axovant Sciences employs 69 workers across the globe.

How can I contact Axovant Sciences?

Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.


MarketBeat Community Rating for Axovant Sciences (NASDAQ AXON)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  419
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Axovant Sciences (NASDAQ:AXON)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 3 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.36)
Consensus Price Target: $14.68 (194.22% upside)

Consensus Price Target History for Axovant Sciences (NASDAQ:AXON)

Price Target History for Axovant Sciences (NASDAQ:AXON)

Analysts' Ratings History for Axovant Sciences (NASDAQ:AXON)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/12/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
11/10/2017Piper Jaffray CompaniesReiterated RatingHoldN/AView Rating Details
11/3/2017Chardan CapitalReiterated RatingSell$3.00N/AView Rating Details
11/1/2017Robert W. BairdReiterated RatingHold$6.00N/AView Rating Details
10/19/2017HC WainwrightReiterated RatingBuyN/AView Rating Details
9/27/2017Jefferies Group LLCReiterated RatingBuy$12.00HighView Rating Details
9/26/2017Evercore ISIReiterated RatingOutperform$30.00 -> $9.00HighView Rating Details
9/26/2017Cowen and CompanyReiterated RatingOutperform$30.00 -> $25.00HighView Rating Details
9/26/2017JMP SecuritiesReiterated RatingOutperform$36.00 -> $19.00N/AView Rating Details
6/14/2017CIBCBoost Price TargetOutperform -> Outperform$26.00 -> $30.00HighView Rating Details
12/20/2016LaidlawInitiated CoverageSell$7.50N/AView Rating Details
6/30/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Axovant Sciences (NASDAQ:AXON)

Earnings by Quarter for Axovant Sciences (NASDAQ:AXON)

Earnings History by Quarter for Axovant Sciences (NASDAQ AXON)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018        
8/7/2017Q1 2018($0.53)($0.65)ViewN/AView Earnings Details
6/13/20173/31/2017($0.51)($0.53)ViewN/AView Earnings Details
2/14/2017Q3($0.45)($0.48)ViewN/AView Earnings Details
8/15/2016Q1($0.36)($0.38)ViewN/AView Earnings Details
6/6/2016Q4 2016($0.30)($0.30)ViewN/AView Earnings Details
2/9/2016Q315($0.15)($0.64)ViewN/AView Earnings Details
11/2/2015Q215($0.24)($0.12)ViewN/AView Earnings Details
8/11/2015Q115($0.10)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Axovant Sciences (NASDAQ:AXON)
2017 EPS Consensus Estimate: ($1.76)
2018 EPS Consensus Estimate: ($1.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.34)($0.34)($0.34)
Q2 20172($0.48)($0.37)($0.43)
Q3 20173($0.57)($0.40)($0.48)
Q4 20173($0.58)($0.43)($0.51)
Q1 20182($0.55)($0.53)($0.54)
Q2 20182($0.65)($0.52)($0.59)
Q3 20182($0.54)($0.22)($0.38)
Q4 20182($0.51)($0.26)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Axovant Sciences (NASDAQ:AXON)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Axovant Sciences (NASDAQ AXON)

Insider Ownership Percentage: 72.50%
Institutional Ownership Percentage: 99.69%
Insider Trades by Quarter for Axovant Sciences (NASDAQ:AXON)
Institutional Ownership by Quarter for Axovant Sciences (NASDAQ:AXON)

Insider Trades by Quarter for Axovant Sciences (NASDAQ AXON)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017David HungInsiderBuy539,375$18.54$10,000,012.50View SEC Filing  
4/17/2017W Anthony VernonDirectorBuy53,937$18.54$999,991.98View SEC Filing  
3/10/2016Mark AltmeyerInsiderBuy2,300$11.14$25,622.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Axovant Sciences (NASDAQ AXON)

Source:

Social Media

Financials

Chart

Axovant Sciences (NASDAQ AXON) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.